Robert C, et al. - Via two trials involving previously 563 untreated patients with metastatic melanoma, the contributors intended to review beneficiary actions of the combination therapy with BRAF and MEK inhibitors and determine the 5-year survival rates and clinical characteristics of the patients. Significantly association among both progression-free survival and overall survival with several baseline factors were noted during multivariate analysis. An improved long-term outcome, with an overall survival rate in one-third of the patients, was assessed. Patients who had unresectable or metastatic melanoma with a BRAF V600E or BRAF V600K mutation long-term benefits of dabrafenib plus trametinib were concluded.